REPORTS that cancer and autoimmune disease drug rituximab could also treat Chronic Fatigue Syndrome (CFS) have been refuted in a new Griffith University study.
To be published in BMC Pharmacology and Toxicology, the study by Griffith's National Centre for Neuroimmunology and Emerging Diseases (NCNED) concluded that the use of rituximab in CFS patients could incur problems with their immune cells and is not beneficial as a treatment.
Natural Killer cells have vital functions in fighting viruses, bacteria and tumours, said Scientific Co-Director of NCNED Professor Sonya Marshall-Gradisnik, adding that rituximab significantly impaired these functions.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Mar 18
